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Buthionine sulfoximine (BSO), a specific inhibitor of gluta-
:hione synthesis, showed variable growth-inhibitory activity 
In different tumor cell lines with a high degree of inhibitory 
activity against melanoma-derived cell lines. A correlation 
between BSO growth-inhibitory effects and cellular glutathi-
~ne peroxidase activity was observed. In contrast, no correla-
tion was demonstrated between the response to BSO and 
cellular tyrosinase, y-glutamylcysteine synthetase, glutathi-
one transferase, y-glutamyl transpeptidase, or glutathione re-
ductase activities. BSO enhanced 3,4-dihydroxybenzyla-
~ine (3,4-0HBA) (fourfold) and melphalan (threefold) in 
Vitro cytotoxic activity as determined by inhibition of ON A 
B uthionine sui fox imine depletes intracellular glutathi-one (GSH) by inhibiting y-glutamylcysteine synthe-tase, the rate-limiting enzyme in GSH synthesis. Be-cause BSO is relatively non-toxic in vivo compared to . other GSH-inhiblting sulfoximine homologs [1], BSO 
IS currently in clinical trial in combination anticancer drug therapy 
With agents that are detoxified by GSH. The potentiation by BSO of 
the effects of cytotoxic anticancer agents has been investigated in 
Vitro [2 -4] and in tumor-bearing animals [5] . Hamilton et al have 
shown that BSO can potentiate drug cytotoxicity in vitro in resist-
ant human ovarian cancer cell lines exposed to doxorubicin, mel-
~halan, and cisplatin [1]. Barranco et al demonstrated that 10-50 
tUnes increases in resistance to melphalan in human gastric carci-
nOma was preceded by a 1.5-3 times elevation in GSH levels [6]. 
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Abbreviations: 
bid: twice daily 
BSO: buthioninc sulfoximine 
3,4-DHBA: 3,4-dihydroxybenzylamine 
EDTA: ethylenediamine tetraacetic acid 
GSH: glutathione 
GSSG: oxidized glutathione 
Ip: intraperitoneally . 
NADPH: nicotinamide-adenine-dinucleotide phosphate (reduced 
form) 
po: by mouth 
qd: every day 
synthesis in human melanoma cells and this enhancement 
was dependent on the duration of exposure to drug. BSO 
demonstrated in vivo antitumor activity in B16 melanoma-
bearing mice prolonging survival by 29% and in combination 
with 3,4-0HBA resulted in a slight (48% versus 38%) in-
crease in life span as compared to 3,4-0HBA alone. The 
combination ofBSO and melphalan, however, increased the 
life span of B 16 melanoma-bearing mice by 170%, as com-
pared to melphalan alone (80%). These studies demonstrate a 
unique in vivo antimelanoma activity ofBSO.J Invest Derma-
toI99:289-293, 1992 
We have shown that BSO inhibits the growth of several human 
and murine melanoma cell lines in vitro, with minimal effect on a 
variety of other neoplastic cell lines [7]. Kable et al [8] have shown 
selective sensitivity of melanoma cells to BSO with longer periods 
of exposure (e.g., 6-d exposure). 
Others found that 3,4-DHBA and other catecholamine analogs 
demonstrated significant antitumor activity against human and 
murine cancer cells in vitro and in vivo [9-11]. Initial experiments 
suggested that the cytotoxic activity was related in part to the inacti-
vation of the sulfhydryl-dependent enzymes involved in DNA syn-
thesis (e.g., DNA polymerase, thymidylate synthetase, ribonucleo-
tide reductase) by quinone oxidation products [12] . The inhibition 
of thymidylate synthetase and DNA polymerase activity in cell-free 
lysates by 3,4-DHBA were shown to require oxidation of the drug 
[13]. Because the addition of GSH (the major cellular antioxidant) 
to quinones is a very rapid non-enzymatic reaction, the metabolic 
fate of quinone oxidation products is mainly dependent on the activ-
ity of the enzymes of the GSH system that are involved in control of 
tissue sulfhydryl content [14,15]. These circumstances suggested 
that modulation of GSH metabolism might influence the cytotoxic 
activity of dihydroxybenzylamine and endogenously produced mel-
al11n precursors. 
In this study we demonstrate the in vivo antitumor activity of 
BSO alone in B16 melanoma as well as BSO enhancement of anti-
melanoma activity of 3,4-DHBA and melphalan. The increased 
sensitivity to BSO in vitro was shown to correlate best with low 
intracellular GSH peroxidase levels. 
MATERIALS AND METHODS 
Chemicals L-buthionine-(S,R)-sulfoximine, 3,4-dihydroxyben-
zylarnine, and 4-[bis(2-chloroethyl)amino]-L-phenylalanine (mel-
phalan) were purchased from Sigma Chemical Co. (St. Louis, MO). 
T -butyl hydroperoxide and glycylglycine were purchased from Al-
drich Chemical Co. (Milwaukee, WI). MethyPH-thymidine and 
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3,5-3H-tyrosine were purchased from New England Nuclear (Bos-
ton, MA). All other reagents were of analytical grade and were 
purchased from Sigma Chemical Co. (St. Louis, MO). 
Cell Lines The origin and maintenance of the human melanoma 
cell lines SK-MEL-30, SK-MEL-28, SK-MEL-2, RPMI-7951, and 
murine B 16 melanoma cell lines have been previously described [7]. 
All cell lines are clonal. The origin and maintenance of the human 
squamous cell carcinoma cell line SCC-25 and the murine leukemia 
cell line L1210 have been described [7]. CCRF-CEM is a T-Iym-
phoblastoid cell line and was obtained from American Type Culture 
Collection. The CCRF-CEM cell line was maintained in Eagle's 
minimum essential medium additionally supplemented with 10% 
fetal calf serum, 2 mM glutamine, 100 units of streptomycin, and 
100 J1.g penicillin/ml. The human melanocyte cell lines M191 and 
M352 were maintained in melanocyte growth medium containing 
5 J1.g/ml insulin, 0.5 J1.g/ml hydrocortisone, 10 ng/ml phorbol12-
myristate-13-acetate, 1 ng/ml basic fibroblast growth factor, genta-
micin, and amphotericin-B obtained from Clonetics (San Diego, 
CA) [16]. All cultures were maintained in a 5% CO2 humidified air 
incubator at 37 ° C. 
Cell lysates were prepared from cell suspensions and monolayers. 
Cell monolayers were trypsinized and added immediately to an 
equal volume of complete medium containing 10% fetal bovine 
serum. Cells were washed 2 times with 0.9% NaCI and the pellet 
was resuspended in 20 mM tris containing 1 mM dithioerythritol 
(pH 7.4). The resuspended cells were sonicated with a Branson 
sonifier (model 185) at a 3.5 setting with three pulses of20 seconds 
durations and centrifuged at 12,000 rpm for 20 min. The superna-
tant was decanted and stored at -70 ° C. 
Biochemical Assays 
Tyrosinase: Tyrosinase activity was assayed by a modification of 
the procedure of Halaban and Lerner [17]. In situ tyrosinase levels 
were determined by measuring incremental 3H20 formation from 
3,5-3H-tyrosine. 
Glutathione levels were measured in the following manner. Sul-
fosalicylic acid was added to celi lysates at a final concentration of 
5% (w Iv) and the samples left on ice for 15 min to precipitate 
cellular proteins. The mixture was then spun at 12,000 rpm for 
10 min in an Eppendorf centrifuge. The supernatant was aspirated 
and used for subsequent glutathione determinations. The assay for 
total glutathione (reduced and oxidized) was carried out by the 
enzyme-recycling method under conditions similar to those de-
scribed by Tietze [18]. Total glutathione concentration is expressed 
as nmoles GSH/mg protein. 
GSH Peroxidase: GSH peroxidase activity was measured by a modi-
fied method of Flohe and Gunzler [19]. The rate of glutathione 
oxidation was measured by adding 400 III of 0.1 M phosphate 
buffer (pH 7.0), 200 J1.1 cell lysate, 100 J1.1 oxidized glutathione 
(GSSG) reductase (0.24 U) and 100 III GSH (1 mM). The mixture 
was pre-incubated for 10 min at 37°C and 100 III of nicotinamide-
adenine-dinucleotide phosphate (reduced form) (NADPH) solu-
tion (150 11M) and 100 III of pre-warmed hydroperoxide solution 
(1.2 mM t-butyl hydroperoxide) added. The decrease in absorbance 
was measured spectophotometrically at 340 nm and the reaction 
rate obtained by subtracting the non-enzymatic effects from the 
overall reaction rate. 
GSH Transferase: GSH transferase activity was assayed by a modi-
fied method of Habig et al [20]. The incubation mixture for deter-
mining GSH transferase activity consisted of 100 III cell lysate, 
2 mM GSH, 2 mM l-chloro-2,4-dinitrobenzene in a 125 mM 
phosphate buffer (pH 6.5) at a final volume of 1 ml. The formation 
of S-2,4-dinitrophenylglutathione was monitored spectrophoto-
metrically at an absorbance of340 nm, e340 = 9.6 cm- I mM- l . A 
unit of enzymatic activity is defined as the amount of enzyme cata-
lyzing the formation of 1 J1.mol of S-2,4-dinitrophenylglutathione 
per minute and specific activity was expressed as units/mg protein. 
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GSH Reductase: GSH reductase in cellular Iysates was assayed by a 
modification of the method of Carlberg and Mannervik [21] . The 
incubation mixture consisted of 100 - 200 J1.1 of cell lysate, 1 ruM 
GSSG, 0.5 mM ethylenediamine tetraacetic acid (EDTA), 0.1 ruM 
NADPH in a 125-mM phosphate buffer (pH 7.2). The formation of 
NADP+ was monitored spectrophotometrically at an absorbance of 
340 nm. 
y-Glntamyl Transpeptidase Y-Glutamyl transpeptidase activity 
was measured by adding 100 J1.1 of the cell lysate to 900 J1.l of the 
transpeptidase substrate solution containing 5 mM L-a-glutamyl-
p-nitroanilide, 20 mM glycylglycine, 75 mM NaCI and 50 ruM 
tris-HCI buffer, pH 8.0. The reaction mixture was incubated at 
37°C and the absorbance was measured every 15 min for 2 h spec-
trophotometrically at 410 mm [22]. In the presence of enzyme, 
L-glutamyl-p-nitroanilide donates a glutamyl group to glycyl gly-
cine (acceptor) forming the conversion products p-nitroaniline and 
glutamyl glycyl glycine. The activity was expressed as micromoles 
of p-nitroaniline released/min/mg protein. A molar extinction co-
efficient of 10.4 cm-IM-I was used for absorbance conversions. 
Y-Glutamylcysteine: y-Glutamylcysteine synthetase activity was 
determined from the rate of formation of adenosine diphosphate 
(ADP) (assumed to be equal to the rate of oxidation ofNADPH~ as 
calculated from the change in absorbance at 340 nm in reactIOn 
mixtures containing (final volume, 1.0 ml) tris buffer (0.1 M; pH 
8.0),150 mM KCI, 5 mM Na2ATP, 2 mM phosphoenolpyruvate, 
10 mM L-glutamate, 10 mM L-aminobutyrate, 20 mM MgCI2, 
2 mM Na2EDTA, 0.2 mM NADPH, 2.5 units of pyruvate kinase, 
and 2.5 units of lactate dehydrogenase [23]. . 
In Vivo Antitumor Studies Five- to six-week-old B6D2FI micE 
were obtained from Taconic Inc., Germantown, NY. Groups ~ 
nine mice were inoculated introperitoneally (ip) with approlCl-
mately 1 X 106 B16 melanoma cells on day 0, and treatments were 
begun on day 1 following standard National Cancer Institute pr~to­
cols. All compounds administered ip were given in sterile sahne. 
The increase in survival (ILS) was calculated according to the for-
mula percent ILS = [(T/C) - 1] X 100, where T and C are the 
median survival rate in days for the treated and control grouPd respectively. All animals were weighed on days 1 and 9, and 9-
weight changes were calculated as a percentage. 
RESULTS 
Biochemical Studies Table I shows the differential sensitivity 
of melanoma and non-melanoma cell lines to the growth-inhibito:J 
activity ofBSO. Because free radicals are generated during melanll} 
synthesis and might be responsible for the increased sensitivity ° 
some of these cell lines to the growth-inhibitory effects ofBSO, ,:,e 
determined if a correlation existed between in situ tyrosinase actiV-
ity and sensitivity to BSO. . . d 
The SK-MEL-30 cell line has the highest tyrosinase actiVity ar 
is the most susceptible to BSO cytotoxicity. However, twO me ad 
noma cell lines low in tyrosinase activity (e.g., RPMI-79.5~ an f 
B16-wt) were also susceptible to the growth-inhibitory actiVity ° 
BSO (ICso < 100 11M) as was a non-melanoma (tyrosinase negjj 
tive) cell line (ICso = 23 11M with the human leukemia CEM ce 
line). Phenylthiourea, a specific inhibitor of tyrosinase, did tot 
block the inhibitory activity of BSO in the SK-MEL-30 ceIl I.ne 
(data not shown), although it effectively suppressed tyrosinase aCt!v-
ity. The heavily pigmented normal human melanocyte ceil te 
M191 had an ICso value of greater than 1 roM, whereas the eSf pigmented human melanocyte cell line M352 had an ICso valuedo_ 531 11M confirming that tyrosinase activity is not an important e 
terminant of sensitivity to BSO cytotoxicity. . d ·f 
We examined total GSH levels in each cell line and determine SB 
a correlation with BSO sensitivity existed (Table II). Tota! G 
levels did not correlate with a sensitivity to the growth-inhlb~~~ 
activity ofBSO. Sensitive cell lines SK-MEL-30 and CEM had 
levels similar to that found in insensitive L1210 cell line. 
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Table I. Comparison of Growth-Inhibitory Effect of BSO and 
Tyrosinase Activity 
Tyrosinase BSO IGso (,uM)h 
Cell Line Activity" 48 H 72H 
Melanoma 
SK-MEL-30 17,696 18 10 
RPMI-7951 510 28 30 
B16-Fl 5,043 77 NT' 
B16-wt 748 100 NT 
SK-MEL-2 303 >1000 670 
SK-MEL-28 442 >1000 >1000 
Non-Melanoma 
CEM NT >1000 23 
11210 NT >1000 >1000 
SCC-25 0 >1000 >1000 
Melanocyte 
M352 3.404 531 NT 
M191 28,169 NT >1000 
M' Tyrosinase activity wa; determined using the in situ assay described in Materials atld 
ethods and is expressed as cpm/50,OOO cells/60 min. 
4 'Cells were incubated with various concentrations of BSO(O.1 p.M to 1 mM) f?r 
8-72 h. IC,o values represent the concentratton of drug causmg a 50% reductton m 
growth. All determinations were done in triplicate. 
, NT, not tested. 
We next investigated the activities of the enzymes central to the 
Illetabolism of GSH to examine the potential correlation of these 
enzymatic activity levels with BSO cytotoxicity. Because BSO di-
rectly inhibits y-glutamyl cysteine synthetase, these enzyme levels 
Were examined for correlative comparison to BSO sensitivity. 
Glutathione peroxidase was chosen because H 20 2 is generated 
Specifically and uniquely by melanoma cells during melanin synthe-
SIS .. Ito et al [24] demonstrated the production of H 20 2 from the 
OXidation of 5-S-cysteinyldopa, an intermediate in the metabolic 
conversion of L-dopa to phaeomelanins. 
l-glutamyl transpeptidase levels were chosen because of the im-
p led role of this enzyme in the conversion of glutathione dopa 
adducts to cysteinyl dopa adducts in melanoma tissue [25]. y-gluta-
Illyl transpeptidase activity, usually high in tumors, is deficient in 
redox-sensitive cells. Low amino acid turnover might decrease re-
SiStance to the stress of externally and possibly internally generated 
Oxygen radicals [26]. 
The enzyme glutathione transferase was examined because this 
enzyme is involved in the detoxification of various electrophilic 
d
cytotoxic agents, including quinones formed by the oxidation of 
Opa. 
GSH peroxidase activities were determined in cell-free extracts in 
Table II. GSH Metabolic Enzymes in Melanoma and Non-
----
Melanoma Cell Lines 
GSH GSH 
~llLine Peroxidase" Reductase' y-GT' 
A1elanoma 
SK-MEL-30 4.08 35.5 0.18 
R.PMI-7951 1.65 36.2 0.31 
B16-F1 3.65 NT' 4.37 
N SK-MEL_28 9.32 19.1 0.40 
on-Melanoma 
CEM 2.89 NT 0.74 
SCC-15 9.16 NT 5.24 
~210 12.30 27.7 1.55 
: ~moles NADPH oxidized/min/mg protein. 
'N moles NADPH oxidized/min/mg protein. 
GSH 
Transferase" 
232.2 
97.3 
218.3 
87.5 
NT 
NT 
40.9 
IN moles p-nitroaniline released/min/mg protein. 
'N moles S-2,4-dinitrophenylglutathione formed/min/mg protein. 
fN moles NADH oxidized/min/mg protein. 
, N~oles GSH/mg protein. 
I not tested. 
Total 
y-GCS' GSHf 
3.42 27.3 
2.26 10.6 
5.06 5.0 
3.11 16.7 
NT 20.1 
2.56 5.8 
5.69 21.1 
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Table III. Time-Dependent Enhancement of 3,4-DHBA and 
Melphalan Inhibition in 3H-TdR Incorporation by BSO in 
Human Melanoma Cells' 
3,4-DHBA ICso (,uM) Melphalan ICso (,uM) 
Time (h) -BSO +BSO -BSO +BSO 
0 695 760 477 375 
2 436 443 217 148 
24 349 <50 148 31 
48 205 <50 NTh NT 
• Human SK-MEL-28 melanoma cells were pre-incubated with 100 p.M BSO for 24 
h. Cells were then exposed to 'H-TdR for 90 min in the presence of drug(s). IC," values 
represent the concentration of drug causing a 50% reduction in 'H-TdR incorporation. 
, NT, not tested. 
four separate experiments. The results reported in Table II are from 
a representative experiment. Low levels of GSH peroxidase were 
found to correlate best with the sensitivity of cell lines to BSO. The 
three sensitive melanoma cell lines had GSH peroxidase activity 
that was less than 4.1 units (1 unit = 1 nmol NADPH oxidized/ 
min/mg protein). The non-melanoma cell line CCRF-CEM was 
also sensitive to BSO (e.g., ICso = 23 JlM after a 3-d exposure) and 
had low GSH peroxidase activity (2.9 units). The insen~itive mela-
noma cell line (e.g., SK-MEL-28) and the insensitive non-mela-
noma cell lines had GSH peroxidase activity greater than 9.2 units. 
GSH transferase levels (total activity) did not correlate with BSO 
toxicity. GSH transferase activity was highest in the most heavily 
pigmente~ ~elliines (SK-MEL-30 an? B16-F1) that had GSH trans-
ferase actiVity two- to threefold higher than those of non-pig-
mented melanoma cell lines and fivefold higher than levels found 
with the L1210 leukemia cell line. 
BSO sensitivity did not correlate with GSH reductase activity. 
Approximately equal GSH reductase activities were observed in the 
four cell lines tested, two sensitive and two insensitive to BSO. 
The membrane-bound enzyme y-glutamyltranspeptidase is in-
volved in the transport of substrates essential for GSH synthesis. 
y-glutamyl transpeptidase levels did not correlate with the sensitiv-
ity of cell lines to BSO and a 30-times difference was found among 
the various cell lines. 
y-glutamylcysteine synthetase is involved in the synthesis of GSH 
and is specifically inhibited by BSO. Levels of y-glutamylcysteine 
synthetase did not correlate with the growth-inhibitory activity of 
BSO: A narrow range of activity was found to exist among the six 
cell hnes tested (e.g., 2.S-times difference between the highest and 
lowest cell levels). 
BS~ Cytotoxicity Experiments BSO enhanced the cytotoxic 
actiVity of 3,4-DHBA and melphalan in human melanoma cells as 
determined by the inhibition of DNA synthesis using 3H-thymi-
dine incorporation. Table III shows that the enhancement increased 
as the duration of exposure to melphalan or 3,4-DHBA increased. 
For melphalan, a 27% enhancement in activity was observed in the 
presence ofBSO when the drug and label were administered simul-
taneously. Conversely, a 2-h exposure to melphalan, followed by a 
90-min exposure in the presence oflabel caused a 47% increase with 
BSO. When the duration of exposure was increased to 24 h, a 378% 
enhancement in activity was observed. 
BSO also enhanced the cytotoxic activity of 3,4-DHBA in 
human melanoma cells as determined by the inhibition of 3H-thy-
midine incorporation. The 3,4-DHBA cytotoxic activity was not 
enhanced by BSO when administered simultaneously with label or 
after a 2-h exposure. After a 24- or 48-h exposure, BSO increased 
the cytotoxic activity of 3,4-DHBA by greater than 400%. 
In Vivo Studies BSO was tested for antitumor activity by two 
different routes of administration, by mouth (po) and ip, in B16 
melanoma in B6D2Ft mice (Table IV). Mice treated ip at a dose of 
200 or 400 mg/kg/injection twice daily (bid) from day 1 to day 9 
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Table IV. Effects of BSO and 3,4-DHBA on the Survival of Mice Bearing IP B16 Melanoma Tumors 
Group Day of Death Range Median ILS (%)' 
200 mg BSOb 21,21,22,22,22,23,23,25,26 21-26 22 5 
400 mg BSO' 20,22,22,22,23,25,25,25,26 20-26 23 10 
BSO in H 20d 23,23,23,25,26,27,28,28,29 23-29 26 24g 
BSO in H 2O' 23,24,26,27,27,27,27,28,28 23-28 27 29g 
3,4-DHBAf 20,26,28,28,29,29,30,30,30 20-30 29 38g 
3,4-DHBA and BSO 27,28,29,29,31,32,33,36,36 27-36 31 48g 
Control 20,20,21,21,21,21,21,22,22 20-22 21 
• Three separate experiments were performed and results reported are from a representative experiment. % increase in life span, (T /e-I) X 100; T, median survival of treated mice; 
e, median survival of untreated mice. 
• Administered ip, bid days 1-9, 200 mg/kg/injection. 
' Administered ip, bid days 1-9. 400 mg/kg/i~ection. 
J Administered ip. bid days 1.400 mg/kg/injection; po in the drinking water at a 20 mM concentration day 1-9. 
, Administered ip. bid day I. 400 mg/kg/injection; po in the drinking water at a 20 mM concentration day 1-15. 
I Administered ip. qd. 400 mg/kg/injection. day 1-9. 
g P < 0.01. 
had a non-statistically significant (p > 0.1) increase in life span of 
5% in comparison to control animals. BSO ip treatments of 400 
mg/kg/injection bid days 1 - 9 resulted in a 10% increase in sur-
vival. The response to BSO was enhanced in mice maintained on 
drinking water containing 20 mM BSO. BSO administered ip, bid 
on day 1 (400 mgjkgjinjection) and then administered po in the 
drinking water (20 mM) from day 1 - 9 resulted in a 24% increase in 
survival (p < 0.01) . When the length of po administration ofBSO 
was prolonged to day 15, a slight increase in the animals' survival 
resulted (e.g., from 24% to 29%). Control animals experienced a 
1 % increase in their body weights as determined by the means taken 
day 1 and day 9. BSO administered bid (5 and 10 mgjkgjinjection) 
resulted in a·O.4% and 0.9% decrease in weight, respectively, wher-
eas BSO given po resulted in a 0.3% decrease in weight. 
BSO was tested in combination with 3,4-DHBA for in vivo anti-
tumor activity in B16 melanoma (Table IV). When 3,4-DHBA was 
given ip, qd at a dose of 400 mgjkgjinjection there was an incre;tsed 
survival rate of 32% as determined by the mean value (38% median 
value). When 3,4-DHBA was given in combination with BSO, the 
survival rate increased to 49% (48% median value). The 3,4-DHBA 
and BSO combination increased the average life span of the animals 
by 50% over that of 3,4-DHBA alone. 
Table V describes the increase in in vivo antimelanoma activity of 
melphalan by BSO. Melphalan given once on day 7 at a dose of 10 
mgjkgjmouse resulted in an increase in survival of 80%, whereas 
melphalan in combination with BSO resulted in an increase of 
170%. The melphalan and BSO combination significantly (p < 
0.01) increased the life span of the treated mice by 113% more than 
melphalan alone. These results were similar to those observed with 
other experimental tumors, but indicate a high degree of activity in 
the generally resistant B-16 model. 
DISCUSSION 
Sensitivity to BSO in melanoma cells might result from the loss of 
an ability to scavenge radicals generated from endogenous [27] or 
exogenous sources [28]. H20 2 and lipid peroxides are generated in 
situ and cells are normally protected from their toxicity because they 
contain the detoxifying enzymes catalase and glutathione peroxi-
dase [29]. Melanoma cells in comparison to other neoplasms gener-
ate significant HzOz through the synthesis of melanin. H202 was 
demonstrated to be involved in the cytotoxic activity of 5-S-cys-
teinyldopa, an intermediate in the metabolic pathway from L-dopa 
to the red-brown pigment pheomelanin [24]. Tumor systems show 
a differential sensitivity to generated peroxides depending ~n t~e 
levels of GSH peroxidase, GSH reductase, and GSH [30]. Little IS 
known about the level of these substances in melanoma cells and 
how these levels might relate to the toxic effects observed wit~ 
BSO. Although BSO inhibits y-glutamylcystdne synthetase, senSI-
tivity of tumor cells did not correlate with the latter's activity. 
Tumor cell sensitivity to BSO appears to correlate best with loW 
GSH peroxidase activity. GSH peroxidase is a selenoenzyrne 111-
volved in the detoxification of H20 2 and a large variety of organiC 
hydroperoxides, including lipid hydroperoxides [31]. The gro~thd 
inhibitory effect of BSO in melanoma cells appears to be mediate 
indirectl y. . 
Dorr et al demonstrated that BSO possessed significant cytotoX~C 
activity to various neoplastic cell lines, but despite the intrigu1l1g In 
vitro sensitivity to BSO they were unable to demonstrate significant 
antitumor activity in vivo [32] . BSO did not prolong survival J;. 
mice bearing L-121O leukemia nor mice implanted ip with MOP 
315 plasmacytomas. We have shown that BSO as a single agent 
does demonstrate significant in vivo antimelanoma activity. .' 
BSO also moderately enhanced the in vivo antimelanoma a~tlVl1 
of 3,4-DHBA, possibly by depleting GSH, which blocks OXldlzel_ 3,4-DHBA from expressing its inhibitory activity with sulfbydry 
dependent enzymes involved in DNA synthesis. 1-
BSO failed to cause a significant increase in the life span of ~e 
phalan-treated L1210 bearing B6DzF1 mice despite a 90% reduct1~n 
in tumor GSH concentrations [33]. In contrast to the find1l1g. In 
L1210 leukemia, studies with a human ovarian carcinoma celll;ne 
have shown that BSO significantly prolonged survival in melpha an 
treated nude mice [34,35]. I 
. e a-
In summary, BSO appears to demonstrate a specific antUn b _ 
noma effect that might be the consequence of the unique meta a 
Table V. Effects of BSO and Melphalan on the Survival of Mice Bearing IP B 16 Melanoma Tumors ____ --------------------------------------~--------------------------~------------------------------
Group Day of Death Range Median ILS (%). --------------------~--------------------~--------------------~~------------------------~--------
BSOb 
Melphalan' 
BSO and Melphalan 
Control 
18,22,22,23,23,23,24,24 
29,32,35,35,36,36,36,36,37 
35,38,43,45,63,64,65,67 
19,20,20,20,20,20,21,22,22 
18-24 
29-37 
35-67 
19-22 
23 
36 
54 
20 
15d 
80d 
170d 
--------
-------------------------------------------------------------------------------------------------------- 'e' C' 
• Three separate experiments were performed and results are from a representative experiment. % increase in life span, (T /e -I) X 100; T. median survival of treated mlC • 
median survival of untreated mice. 
• Administered ip. bid. day 1.400 mg/kg/injection; po in the drinking water day 1 - 15. 
, Administered as a single ip i~ection , 10 mg/kg/mouse. day 7. 
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lism of melanoma cells. BSO is capable of enhancing the antimelan-
oma effect of melphalan and the experimental agent 3,4-DH~A. 
The applicability of these findings will depend on an un.derstandmg 
of possible drug interactions as well as an understandmg of GSH 
metabolism in the tumor systems in which these therapies may be 
used. 
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